《股市簡訊》中國復宏漢霖一度漲4.7%，肺癌聯合療法臨床試驗獲批

路透中文

03/17

《股市簡訊》中國<a href="https://laohu8.com/S/02696">復宏漢霖</a>一度漲4.7%，肺癌聯合療法臨床試驗獲批

* 中國復星醫藥2196.HK600196.SS旗下研發生物類似藥的復宏漢霖2696.HK周二早盤一度升4.7%，早市收高1.7%。

* 該公司此前公告稱，HLX07聯合漢斯狀（斯魯利單抗注射液）和化療治療晚期鱗狀非小細胞肺癌的臨床試驗申請獲國家藥品監督管理局批准。

* 復宏漢霖今年迄今勁漲21.1%，同期恒生指數.HSI上揚1.8%。

* 恒⽣⽣物科技指數.HSBIO早市收高2.3%。（完）

更多股市簡訊請點選CN-CMN-HOT

(發稿徐凱文；審校吳雲凌)

((kaiwen.xu@thomsonreuters.com))

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2620008417"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620008417\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620008417?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-17 12:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620008417","market":"us","top_or_hot":-1,"title":"《股市簡訊》中國復宏漢霖一度漲4.7%，肺癌聯合療法臨床試驗獲批","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市簡訊》中國<a href=\"https://laohu8.com/S/02696\">復宏漢霖</a>一度漲4.7%，肺癌聯合療法臨床試驗獲批</title></head><body><p>* 中國<a href=\"https://laohu8.com/S/600196\">復星醫藥</a><span>2196.HK</span><span>600196.SS</span>旗下研發<a href=\"https://laohu8.com/S/000504\">生物</a>類似藥的復宏漢霖<span>2696.HK</span>周二早盤一度升4.7%，早市收高1.7%。</p><p>* 該公司此前公告稱，HLX07聯合漢斯狀（斯魯利單抗注射液）和化療治療晚期鱗狀非小細胞肺癌的臨床試驗申請獲國家藥品監督管理局批准。</p><p>* 復宏漢霖今年迄今勁漲21.1%，同期恒生指數<span>.HSI</span>上揚1.8%。</p><p>* 恒⽣⽣物科技指數<span>.HSBIO</span>早市收高2.3%。（完）</p><p>更多股市簡訊請點選<span>CN-CMN-HOT</span></p><p> (發稿 徐凱文；審校 吳雲凌)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《股市簡訊》中國復宏漢霖一度漲4.7%，肺癌聯合療法臨床試驗獲批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《股市簡訊》中國復宏漢霖一度漲4.7%，肺癌聯合療法臨床試驗獲批\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2026-03-17 12:25</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市簡訊》中國<a href=\"https://laohu8.com/S/02696\">復宏漢霖</a>一度漲4.7%，肺癌聯合療法臨床試驗獲批</title></head><body><p>* 中國<a href=\"https://laohu8.com/S/600196\">復星醫藥</a><span>2196.HK</span><span>600196.SS</span>旗下研發<a href=\"https://laohu8.com/S/000504\">生物</a>類似藥的復宏漢霖<span>2696.HK</span>周二早盤一度升4.7%，早市收高1.7%。</p><p>* 該公司此前公告稱，HLX07聯合漢斯狀（斯魯利單抗注射液）和化療治療晚期鱗狀非小細胞肺癌的臨床試驗申請獲國家藥品監督管理局批准。</p><p>* 復宏漢霖今年迄今勁漲21.1%，同期恒生指數<span>.HSI</span>上揚1.8%。</p><p>* 恒⽣⽣物科技指數<span>.HSBIO</span>早市收高2.3%。（完）</p><p>更多股市簡訊請點選<span>CN-CMN-HOT</span></p><p> (發稿 徐凱文；審校 吳雲凌)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306701.USD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL4T4050CI:1","article_id":"2620008417","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620008417","pubTimestamp":1773721517,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"《股市簡訊》中國復宏漢霖一度漲4.7%，肺癌聯合療法臨床試驗獲批* 中國復星醫藥2196.HK600196.SS旗下研發生物類似藥的復宏漢霖2696.HK周二早盤一度升4.7%，早市收高1.7%。* 該公司此前公告稱，HLX07聯合漢斯狀（斯魯利單抗注射液）和化療治療晚期鱗狀非小細胞肺癌的臨床試驗申請獲國家藥品監督管理局批准。* 復宏漢霖今年迄今勁漲21.1%，同期恒生指數.HSI上揚1.8%。* 恒⽣⽣物科技指數.HSBIO早市收高2.3%。（完）更多股市簡訊請點選CN-CMN-HOT (發稿 徐凱文；審校 吳雲凌) ((kaiwen.xu@thomsonreuters.com))","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","02696":"复宏汉霖","BK1161":"生物科技","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC"},"translate_title":"\"Stock Market Newsletter\" China Fuhong Henlius once rose 4.7%, and the clinical trial of lung cancer combination therapy was approved","themeId":"37684715aaf54a73b9fe52ee56a263cc","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":0.9},"content_text":"《股市簡訊》中國復宏漢霖一度漲4.7%，肺癌聯合療法臨床試驗獲批* 中國復星醫藥2196.HK600196.SS旗下研發生物類似藥的復宏漢霖2696.HK周二早盤一度升4.7%，早市收高1.7%。* 該公司此前公告稱，HLX07聯合漢斯狀（斯魯利單抗注射液）和化療治療晚期鱗狀非小細胞肺癌的臨床試驗申請獲國家藥品監督管理局批准。* 復宏漢霖今年迄今勁漲21.1%，同期恒生指數.HSI上揚1.8%。* 恒⽣⽣物科技指數.HSBIO早市收高2.3%。（完）更多股市簡訊請點選CN-CMN-HOT (發稿 徐凱文；審校 吳雲凌) ((kaiwen.xu@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}